siRNA

siRNA
#Biotechnology platform #Eleven Therapeutics #Seed funding #siRNA #Therapeutics #Undecimal Bio

Seed financing to address ‘liver trap’ in siRNA therapeutic delivery 

Undecimal Bio, a platform biotechnology company advancing targeted delivery of siRNA therapeutics, has announced an oversubscribed $18 million seed financing.   The company is a spin-out from Eleven Therapeutics and will use the funding to expand DELiveri, its AI-enabled platform for identifying conjugates that can direct RNA… Read More

#News

siRNA
#Merck #Mergers and acquisitions #Silence Therapeutics #siRNA

Merck KGaA buys Silence Therapeutics for $1.3 billion

Merck KGaA is to acquire Silence Therapeutics, a biotechnology company developing precision engineered medicines using siRNA technology.   Merck has agreed to acquire Silence in an all-cash transaction with an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion.  “We are pleased to have reached this agreement… Read More

#Business & Investment #News #Trending News

#CatSci #CRISPR #Drug development #Drug discovery #Life science #siRNA

From undruggable to inevitable

Dr Joe Renny, Head of Corporate Development, and Dr Simon Tyler, Chief Commercial Officer, CatSci, discuss the last 15 years of drug development, and what comes next. The American Cancer Society’s 2026 statistics tell a story that should be on the wall of every drug developer. Five-year survival for chronic… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Cancer research #DNA #Genetics / genomics #Oncology #RNA #siRNA

New podcast: The revolutionary impact of understanding genomics

This is the latest episode of the free DDW narrated podcast, titled “The revolutionary impact of understanding genomics”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Open science, genomics, and the quiet revolution in our approach to pharma” and “… Read More

#News

Ageing hands
#Ageing #Healthspan #Junevity #Seed funding #siRNA #Transcriptomics

Biotech raises $10m to address ageing at a cellular level

Junevity, a biotechnology company hoping to extend lifespan and healthspan by resetting cell damage from age-related diseases, has announced $10 million in seed funding led by Goldcrest Capital and Godfrey Capital.  The Junevity RESET platform is based on exclusively licensed research by co-founder Dr Janine Sengstack at the University of… Read More

#Business & Investment #News

Lipid nanoparticle mRNA vaccine
#Drug delivery #Guide #Lipid based nanoparticle (LNP) #mRNA #RNA Therapeutics #siRNA

Lipid nanoparticle formulation: Download the Guide

A new Guide is now available for free download from Cayman Chemical entitled ‘Lipid Nanoparticle Formulation: Basic Concepts & Preparation Procedures‘. Lipid nanoparticles (LNPs) have great potential to revolutionise the development of nucleic acid therapies. Download the Guide to learn more about: The basic concepts and components… Read More

#News

#Drug delivery #Lipid based nanoparticle (LNP) #mRNA #RNA Therapeutics #siRNA

Lipid Nanoparticle Formulation: Basic Concepts & Preparation Procedures

Lipid nanoparticles (LNPs) have great potential to revolutionise the development of nucleic acid therapies. Download the Guide to learn more about: The basic concepts and components of lipid-based drug delivery systems Important considerations for LNP design, stability, and storage Techniques for LNP preparation, characterisation, and functional assessment… Read More

#Intelligence #Resources

siRNA
#Aptamer Group #Aptamers #AstraZeneca #Collaboration #Gene therapy #siRNA

AstraZeneca and Aptamer test liver delivery vehicles with siRNA

Aptamer Group and AstraZeneca have entered a collaboration agreement to evaluate Aptamer’s Optimer fibrotic liver delivery vehicles for the targeted delivery of small interfering RNA (siRNA). Following the encouraging results achieved to-date with Aptamer’s fibrotic liver delivery vehicles, the next phase of the research will explore the potential of the… Read More

#Business & Investment #News

siRNA
#Bone disease #Preclinical investigations #RNA #siRNA #SiSaf

Positive preclinical data for siRNA therapy for osteopetrosis

RNA therapeutics company SiSaf has published positive safety and efficacy data for its siRNA therapy for Autosomal Dominant Osteopetrosis 2 (ADO2). The data demonstrate that siRNA complexed with SiSaf’s silicon stabilised hybrid lipid nanoparticles (sshLNP) was able to significantly downregulate expression of an ADO2-specific mutant gene. Read More

#News

DNA helix
#DNA #Genetics / genomics #RNA #siRNA

Junk DNA: How the dark genome is changing RNA therapies

Listen to this article on the DDW Podcast: Samir Ounzain, PhD, CEO & Co-Founder of HAYA Therapeutics, looks at how a better understanding of our DNA can lead to increased activity for RNA therapeutics. The whole world realised the power of RNA when the Covid-19 pandemic brought us the first mRNA-based… Read More

#Exclusive Content #Opinion

Genetic engineering RNA
#Antisense Oligonucleotides (ASOs) #circular RNAs #Immunology / Virology & Vaccines #mRNA #RNA sequencing #siRNA

World RNA Day: What impact has RNA had on drug discovery?  

1 August was first chosen as World RNA Day in 2018 as a play on AUG (adenine, uracil and guanine), a triple sequence of RNA (called a codon) that initiates protein synthesis by the cell. Since then, it has been observed to publicise the importance of this molecule in the… Read More

#Exclusive Content

siRNA
#DTx Pharma #FDA #Orphan drugs #Rare disease #siRNA

siRNA therapy for rare disease granted orphan status

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to DTx Pharma’s DTx-1252, an investigational small interfering RNA (siRNA) therapeutic for the treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A). CMT1A is a progressive, neuromuscular, autosomal-dominant disease that leads to life-long loss of muscle… Read More

#News

siRNA
#FDA #Orphan drugs #Paediatrics #Rare disease #siRNA #SiSaf

Therapy for rare skeletal disorder granted orphan status

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to SiSaf’s small interfering RNA (siRNA) therapeutic for skeletal disorder Autosomal Dominant Osteopetrosis Type 2 (ADO2). In addition, due to the serious manifestations of this rare disease in children, SIS-101-ADO has been granted Rare Pediatric Disease Designation for… Read More

#News #Regulatory

siRNA
#Biotechnology #Dermatology #Funding #Immuno-dermatology #siRNA

Is this a novel approach to immuno-dermatology? 

Aldena Therapeutics, a biotech company that is pioneering siRNA-based therapies for dermatological indications, has updated its immuno-dermatology pipeline, appointed a Scientific Advisory Board (SAB), and announced $30 million financing by Medicxi.  Pipeline  Under the leadership of Thibaud Portal, CEO of Aldena, the company’s goal is to develop advanced, long-lasting treatments… Read More

#Business & Investment #News

Hepatitis B
#hepatitis #Immunology / Virology & Vaccines #Immunotherapy #Phase II trial #siRNA #VBI Vaccines

Hepatitis B combination restores antibody and T cell responses

Biopharmaceutical company VBI Vaccines has revealed interim data from its Phase II study evaluating the combination of VBI-2601, VBI’s HBV immunotherapeutic candidate, and BRII-835, an HBV-targeting siRNA candidate, in chronically infected hepatitis B (HBV) patients.   The data demonstrate that the combination therapy was generally well-tolerated, restored strong… Read More

#News #Trending News

#Drug development #Drug discovery #GlobalData #siRNA #Therapeutics

Chinese pharma companies eye strategic alliances for therapeutics

The overall potential of siRNA-based therapeutics has attracted Chinese pharma companies to tap opportunities and bring promising innovative therapies across the globe, according to reporting by GlobalData. Against this backdrop, the Chinese pharma companies have increased their focus towards the siRNA pipeline through strategic alliances.  China pharma… Read More

#News #Trending News